“Global Checkpoint Inhibitors for Anti-Cancer Treatment market set to grow to $22bn by 2024” says Visiongain report

28 May 2019
Pharma

Visiongain has launched a new pharma report Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs.

Checkpoint inhibitors have changed the landscape of melanoma treatment in the last few years and advanced it in ways that could not have been possible before. The response rates achieved and survival rates are so much higher than any seen before and metastatic melanoma patients are living much longer. The global checkpoint inhibitor for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

The lead analyst of the report commented "One opportunity for driving growth in the checkpoint inhibitor market is the development of companion diagnostic tests. These tests would be indispensable as they would allow treatment to be given only to those patients who would derive the most benefit from it and not add to the cost burden by eliminating patients who would gain no advantage from using this treatment or would be susceptible to severe side effects such as autoimmune-related effects."

Leading companies featured in the report include AstraZeneca, Plc, Bristol-Myers Squibb Co., Celldex Therapeutics, Inc., Incyte Corporation, Merck & Co., Inc, Novartis, Pfizer, Roche and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever